AcelRx Pharmaceuticals, Inc. (ACRX): Price and Financial Metrics

AcelRx Pharmaceuticals, Inc. (ACRX): $0.86

0.06 (+7.50%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

ACRX Price/Volume Stats

Current price $0.86 52-week high $2.78
Prev. close $0.80 52-week low $0.43
Day low $0.78 Volume 243,500
Day high $0.88 Avg. volume 137,683
50-day MA $0.67 Dividend yield N/A
200-day MA $0.82 Market Cap 14.58M

ACRX Stock Price Chart Interactive Chart >

ACRX POWR Grades

  • ACRX scores best on the Sentiment dimension, with a Sentiment rank ahead of 93.37% of US stocks.
  • ACRX's strongest trending metric is Growth; it's been moving up over the last 161 days.
  • ACRX's current lowest rank is in the Stability metric (where it is better than 4.45% of US stocks).

ACRX Stock Summary

  • The ratio of debt to operating expenses for ACELRX PHARMACEUTICALS INC is higher than it is for about just 0.22% of US stocks.
  • With a year-over-year growth in debt of -100%, ACELRX PHARMACEUTICALS INC's debt growth rate surpasses merely 0% of about US stocks.
  • Revenue growth over the past 12 months for ACELRX PHARMACEUTICALS INC comes in at -59.11%, a number that bests merely 3.8% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to ACRX, based on their financial statements, market capitalization, and price volatility, are ICAD, AEYE, NURO, RPID, and APDN.
  • Visit ACRX's SEC page to see the company's official filings. To visit the company's web site, go to www.acelrx.com.

ACRX Valuation Summary

  • ACRX's price/sales ratio is 20.1; this is 378.57% higher than that of the median Healthcare stock.
  • Over the past 157 months, ACRX's price/earnings ratio has gone up 5.6.

Below are key valuation metrics over time for ACRX.

Stock Date P/S P/B P/E EV/EBIT
ACRX 2023-12-29 20.1 0.7 -0.5 0
ACRX 2023-12-28 22.3 0.8 -0.5 0
ACRX 2023-12-27 21.1 0.7 -0.5 0
ACRX 2023-12-26 21.5 0.7 -0.5 0
ACRX 2023-12-22 21.4 0.7 -0.5 0
ACRX 2023-12-21 21.2 0.7 -0.5 0

ACRX Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at -70.37%.
  • The 3 year net cashflow from operations growth rate now stands at 16.35%.
  • The 4 year net income to common stockholders growth rate now stands at -16.27%.
ACRX's revenue has moved down $768,000 over the prior 33 months.

The table below shows ACRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.521 -30.922 47.136
2022-06-30 2.876 -29.627 45.697
2022-03-31 2.749 -29.228 -34.817
2021-12-31 2.818 -30.002 -35.099
2021-09-30 3.554 -28.325 -36.1
2021-06-30 3.06 -32.506 -36.655

ACRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ACRX has a Quality Grade of F, ranking ahead of 2.01% of graded US stocks.
  • ACRX's asset turnover comes in at 0.041 -- ranking 335th of 680 Pharmaceutical Products stocks.
  • JNJ, ORGS, and ABBV are the stocks whose asset turnover ratios are most correlated with ACRX.

The table below shows ACRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.041 -0.709 -0.606
2021-03-31 0.077 -0.004 -0.552
2020-12-31 0.078 -0.114 -0.640
2020-09-30 0.068 -0.232 -0.616
2020-06-30 0.052 -0.513 -0.580
2020-03-31 0.025 -1.941 -0.632

ACRX Price Target

For more insight on analysts targets of ACRX, see our ACRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.00 Average Broker Recommendation 1.5 (Moderate Buy)

AcelRx Pharmaceuticals, Inc. (ACRX) Company Bio


AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company was founded in 2005 and is based in Redwood City, California.


ACRX Latest News Stream


Event/Time News Detail
Loading, please wait...

ACRX Latest Social Stream


Loading social stream, please wait...

View Full ACRX Social Stream

Latest ACRX News From Around the Web

Below are the latest news stories about ACELRX PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ACRX as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!

William White on InvestorPlace | December 11, 2023

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2023 Earnings Call Transcript

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Welcome to the AcelRx third quarter 2023 financial results conference call. This call is being webcasted live via the events page of the Investors section of AcelRx’s website at www.acelrx.com. This call is property of AcelRx, and any recording, reproduction or transmission […]

Yahoo | November 9, 2023

AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its third quarter 2023 financial results and provided a corporate update.

Yahoo | November 8, 2023

AcelRx to Host KOL Panel Discussion on Current Anticoagulant Use in Dialysis and the Upcoming Niyad™ Clinical Study

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a virtual Key Opinion Leader (KOL) panel discussion on its lead candidate Niyad™ (nafamostat) for use as an anticoagulant in dialysis circuits. The panel will feature two thought-leaders in the nephrology and critical care fields who are also co-authors on a re

Yahoo | November 7, 2023

AcelRx to Host Third Quarter 2023 Financial Results Call and Webcast on November 8, 2023

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2023 financial results after market close on Wednesday, November 8, 2023, then host a live webcast and conference call at 4:30 p.m. Eastern Standard Time/1:30 p.m. Pacific Standard Time to discuss the results and provide an update on the Compan

Yahoo | October 26, 2023

Read More 'ACRX' Stories Here

ACRX Price Returns

1-mo N/A
3-mo 24.66%
6-mo -6.52%
1-year -38.13%
3-year -97.93%
5-year -98.63%
YTD 17.01%
2023 -67.48%
2022 -79.83%
2021 -54.82%
2020 -41.23%
2019 -8.66%

Continue Researching ACRX

Want to see what other sources are saying about Acelrx Pharmaceuticals Inc's financials and stock price? Try the links below:

Acelrx Pharmaceuticals Inc (ACRX) Stock Price | Nasdaq
Acelrx Pharmaceuticals Inc (ACRX) Stock Quote, History and News - Yahoo Finance
Acelrx Pharmaceuticals Inc (ACRX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!